



## Soman Nerve Agent Pretreatment Pyridostigmine

### SNAPP

#### Description

SNAPP (NSN 6505-01-178-7903) (Pyridostigmine Bromide, 30 mg) is a Food and Drug Administration (FDA) approved pretreatment drug intended for protection against the effects of the nerve agent, soman. Given by oral administration, every eight hours, prior to soman exposure, SNAPP works in combination with atropine and 2-PAM (administered after exposure) to allow Warfighters to survive an otherwise lethal exposure to soman. It is not effective if used alone. SNAPP was the first product approved by the FDA under the "animal rule." This rule allows for the approval of medicines based on animal effectiveness studies when those studies cannot be conducted ethically in humans (for example, soman exposure).



#### Mission

To sustain a pretreatment capability to protect the warfighter against the devastating effects of the nerve agent soman.

#### Capabilities

- Chemical Pretreatment
- Protect against lethal effects of soman when used with current fielded therapeutic drugs.

#### Users

US Navy, US Marine Corps, US Army, US Air Force

#### Status

Sustainment

This Fact Sheet was cleared for public release on 6/27/2016.

Point of Contact: Chemical, Biological, Radiological, & Nuclear Information Resource Center (CBRN IRC), CBRN.IRC@mail.mil,  
Toll Free: 1-800-831-4408, Commercial: (309) 782-7349, DSN: 793-7349, Fax: (309) 782-1919